CNTX-4975 OSTEOARTHRITIS DRUG PIPELINE – MARKET INSIGHTS AND FORECASTS UPTO 2032
CNTX-4975 is currently being evaluated as a treatment for moderate to severe knee osteoarthritis (OA) pain. Get more insights into our latest pipeline reports
ELIXCYTE OSTEOARTHRITIS DRUG PIPELINE – MARKET INSIGHTS AND FORECASTS UPTO 2032
ELIXCYTE is an allogeneic stem cell product derived from adipose tissue, designed to regulate the immune system. Read more about Elixcyte Osteoarthritis reports
JTA-004 OSTEOARTHRITIS DRUG PIPELINE – MARKET INSIGHTS AND FORECASTS UPTO 2032
JTA-004 is an innovative treatment in development for managing knee osteoarthritis pain. Get more insights into our JTA-004 Osteoarthritis pipeline reports
AMZ001 OSTEOARTHRITIS DRUG PIPELINE – MARKET INSIGHTS AND FORECASTS UPTO 2032
AMZ001 is a new topical gel formulation of diclofenac, developed specifically to treat knee osteoarthritis (OA) pain. Read more about our pipeline reports.
RTX-GRT7039 OSTEOARTHRITIS DRUG PIPELINE – MARKET INSIGHTS AND FORECASTS UPTO 2032
RTX-GRT7039 (resiniferatoxin) is an investigational drug designed for pain relief in patients with knee osteoarthritis (OA). Get more insights into our reports